Epilepsy

Clobazam as an add-on in the management of refractory epilepsy

Abstract Background Epilepsy effects approximately 1% of the population, with up to 30% of patients continuing to have seizures despite antiepileptic drug treatment. Objectives To assess the efficacy and tolerability of clobazam when used as an add-on therapy for patients with refractory partial onset or generalised onset seizures. Search methods We searched the following databases: […]

Share

Therapeutic monitoring of antiepileptic drugs for epilepsy

Abstract Background This is an updated version of the original Cochrane review published in Issue 1, 2007. The aim of drug treatment for epilepsy is to prevent seizures without causing adverse effects. To achieve this, drug dosages need to be individualised. Measuring antiepileptic drug levels in body fluids (therapeutic drug monitoring) is frequently used to […]

Share

Vitamins for epilepsy

Abstract Background Vitamins have been reported to be effective in controlling certain types of seizures and to prevent some of the harmful effects of antiepileptic drugs (AEDs). In this review we will summarize evidence from randomized controlled trials. Objectives To assess if vitamins improve seizure control, reduce adverse effects of AEDs or improve the quality […]

Share

Anticonvulsants for neonates with seizures

Abstract Background Neonatal seizures are a common problem and most neonates with seizures are treated with anticonvulsants. There is wide variation in clinical practice in both diagnosis and treatment of such seizures and this reflects the lack of clear evidence of the relative benefit and harm of the anticonvulsants used. The routine use of anticonvulsants […]

Share

Remacemide for drug-resistant localization related epilepsy

Abstract Background This is an updated version of the original Cochrane review published in issue 4, 2002. Epilepsy is a common neurological condition, affecting 0.5% to 1% of the population. Nearly 30% of people with epilepsy have seizures that are refractory to currently available drugs. In response to this problem, potential new drugs are being […]

Share

Routine anticonvulsants for treating cerebral malaria

Abstract Background Cerebral malaria is a common complication of Plasmodium falciparum infection, and kills over a million people every year. People with cerebral malaria become unconscious, and often have protracted convulsions. It is unclear whether giving anticonvulsant drugs routinely to people with cerebral malaria will improve the outcome of treatment and prevent death. Objectives To […]

Share

Carbamazepine versus valproate monotherapy for epilepsy

Abstract Background Carbamazepine and valproate are drugs of first choice for epilepsy. Despite the lack of hard evidence from individual randomized controlled trials, there is strong clinical belief that valproate is the drug of choice for generalized epilepsies and carbamazepine for partial epilepsies. Objectives To overview the best evidence comparing carbamazepine and valproate monotherapy Search […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share